Abstract
AbstractManagement of primary orthostatic tremor (POT) remains challenging, and medication is often ineffective.We report the case of a 53-year-old female with orthostatic tremor for 6 years who was refractory to gabapentin, clonazepam, primidone and propranolol. After treatment with 4 mg/day perampanel, she reported almost complete resolution of tremor. The diagnosis of POT was confirmed by tremor analysis using surface electromyography.Our report shows the potential use of the novel AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor antagonist perampanel for the treatment of POT. To date, only two similar patients, one refractory to treatment and the other previously treated with clonazepam only, have been reported. We would like to note that our patient was refractory to all previous therapy and responded to a low dose of perampanel without side effects. The striking clinical improvement suggests a putative role of glutamate in the pathophysiology of orthostatic tremor.
Publisher
Springer Science and Business Media LLC
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Other Tremors;Movement Disorders Phenomenology;2024
2. Isolated slow orthostatic tremor of the trunk;Neurological Research and Practice;2022-10-17
3. Perampanel as a treatment option for orthostatic tremor;Parkinsonism & Related Disorders;2022-09
4. A look back at 3 years of neurological research and practice (NRP);Neurological Research and Practice;2022-04-28
5. Medications used to treat tremors;Journal of the Neurological Sciences;2022-04